Evidence map›Paper›PMID 40163843›Full record

Observational studyRevista medica del Instituto Mexicano del Seguro Social2023

[Quality of life in patients with renal replacement therapy in hemodialysis].

Oscar Alfredo Luna-Ríos, José Oscar Juárez-Sánchez

Abstract readEnglish AbstractObservational Study
In one paragraph

Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Oscar Alfredo Luna-RíosInstituto Mexicano del Seguro Social, Centro Médico Nacional del Bajío, Hospital de Especialidades No. 1, Servicio de Nefrología. León, Guanajuato, México.ORCID 0000-0001-9797-161X
José Oscar Juárez-SánchezInstituto Mexicano del Seguro Social, Centro Médico Nacional del Bajío, Hospital de Especialidades No. 1, Servicio de Nefrología. León, Guanajuato, México.ORCID 0000-0002-3560-7879

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study is carried out to establish the quality of life (QL) of patients with chronic kidney disease (CKD) on renal replacement therapy (RRT) on hemodialysis (HD), since it has been associated with decreased QL in these patients secondary to the medical-surgical interventions that are performed, in addition to the multiple comorbidities and complications that are associated with them. Objective: To establish the QL of patients with terminal CKD who are on RRT on HD. Material and methods: Prospective, cross-sectional, observational and analytical study, with non-probabilistic convenience sampling. The total was of n = 87 patients, who were on RRT on intramural HD. It was carried out a survey to determine their QL. The Kidney Disease Quality of Life-36 (KDQOL-SF36) instrument was applied. Results: It was found that 51 patients (58%) were men, with a mean age of 45.037 (± 15.8663). Among QL results, the following variables were considered bad: assessing their kidney disease, sexual life, quality of sleep, relationship with family and friends, and work quality (p = 0.002, p = 0.001, p = 0.012, p = 0.005, and p = 0.001, respectively). In addition, it was shown that 46 patients (56%) considered that the quality of their health was bad (p = 0.024). Conclusions: In this study it was shown that suffering from CKD and being on RRT in HD produces a bad QL for these patients.

Indexed as

Cross-sectional StudyHemodialysisQuality of lifeRenal Insufficiency

Identifiers

PMID40163843
PMCPMC11960714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.